A Study Comparing Recurrent Use of MSIR, Percocet, and Vicodin at Discharge From the ED

• Status: Withdrawn
• Trial end date: 2021-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This is a prospective randomized, clinical trial comparing recurrent use of Morphine Sulfate Immediate Release (MSIR), Oxycodone/Acetaminophen (Percocet), and Hydrocodone/Acetaminophen (Vicodin) at discharge from the emergency department for opioid-naive adult patients presenting with moderate-to-severe pain. At discharge, patients will be randomized to receive either 5 mg of Oxycodone/Acetaminophen (Percocet) tablet 4 times a day for 5 days, 5 mg of Hydrocodone/Acetaminophen (Vicodin) tablet 4 times a day for 5 days, or 15 mg Morphine Sulfate Immediate Release (MSIR) tablet 4 times a day for 5 days. At 1 month, 3 months, and 6 months patients' prescription's history will be accessed by using the DoctorFirst Drug Database to determine the recurrent use that will serve as a surrogate marker of likeability and abuse liability of each prescribed opioid.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Antonios Likourezos
• Treatments: Acetaminophen; Acetaminophen, hydrocodone drug combination; Hydrocodone; Morphine; Oxycodone

Criteria

Inclusion Criteria:

• ED patient

• 18 and older

• acute to moderate to severe pain

• requires oral opioid medications at ED discharge.

Exclusion Criteria:

• chronic non-cancer and cancer pain,

• patients with history of substance abuse

• patients with opioid use disorder,

• patients simultaneously taking antidepressants, benzodiazepines and other sedative-hypnotics,

• and allergies to any of the medications.